1-4 of 4
Zachary Zimmerman
Close
Sort by
Journal Articles

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Clinical Trials & Observations
Max S. Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C. Schuh
Journal: Blood
Blood (2018) 131 (26): 2906–2914.
https://doi.org/10.1182/blood-2017-09-804658
Published: 2018
Includes: Supplemental data
Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong
Journal: Blood
Blood (2016) 128 (22): 222.
https://doi.org/10.1182/blood.V128.22.222.222
Published: 2016
Journal Articles

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Anthony Selwyn Stein, MD, Max S. Topp, MD, Hagop M Kantarjian, MD, Nicola Goekbuget, MD, Ralf C Bargou, MD, Mark R Litzow, MD, Alessandro Rambaldi, MD, Josep Ribera, MD PhD, Alicia Zhang, PhD, Zachary Zimmerman, MD PhD, Stephen J. Forman, MD
Journal: Blood
Blood (2015) 126 (23): 861.
https://doi.org/10.1182/blood.V126.23.861.861
Published: 2015
Journal Articles

Transplanted Donor APC Co-Stimulatory Molecule Expression Is Required To Elicit Host T Cell Resistance in MHC-Matched Allogeneic BMT Recipients Following Reduced Intensity Conditioning.

Monica Jones, Bruce Blazar, MD, Zachary Zimmerman, PhD, Robert B. Levy, PhD
Journal: Blood
Blood (2006) 108 (11): 620.
https://doi.org/10.1182/blood.V108.11.620.620
Published: 2006